- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Acuson president to leave company
Acuson president to leave companyAcuson of Mountain View, CA, announced that company president and director Daniel Dugan resigned effective March 1. Former Acuson president Robert Gallagher will come out of retirement to serve as president and
Acuson president to leave company
Acuson of Mountain View, CA, announced that company president and director Daniel Dugan resigned effective March 1. Former Acuson president Robert Gallagher will come out of retirement to serve as president and chief operating officer until sometime in June, when a permanent replacement for Dugan will be named. Gallagher, 56, previously was president and chief operating officer.
Dugans departure appears unrelated to the companys recent financial performance. The ultrasound vendor posted revenues of $135 million for the fourth quarter of 1999, an increase of 10% compared with the fourth quarter of 1998, and $475.9 million for the year, compared to $455 million in 1998.
© 2000 Miller Freeman, Inc., a United News & Media company.
- Search again
- Homepage
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
